
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is positioned for strong growth in the coming years with their innovative product offerings and a strong financial foundation. The company's recent Q2/26 production results may have missed estimates, but their Los Reyes PEA outlines a next avenue for growth and their FY2026 guidance is being reiterated. With a diversified geographic presence and continued expansion into new markets, 10x Genomics has a strong competitive advantage over new entrants in the genomics space. Additionally, the company's disciplined operating expense profile and expected growth in high-volume areas such as translational and clinical research demonstrate their ability to maintain profitability despite potential challenges.
Bears say
10x Genomics is facing production challenges as its Q2 AuEq production and sales fell below estimates due to lower-grade and lower-gold-recovery areas at Media Luna. Its recent quarter results align with the guidance of tracking towards the lower end of its reiterated 420-470 koz AuEq guidance range, requiring an increase in H2 grades to meet plans. Additionally, the company's revenues for the quarter grew 1% y/y but instrument revenues declined 36% y/y due to discounting, while operating expenses decreased 18% y/y.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares